정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
---|---|---|---|---|---|---|---|---|---|---|---|
2018 | Recruiting | Clinical Study of Recombinant Novel Coronavirus(COVID-19) Vaccine (CHO Cell) Combined With Influenza Vaccine | Coronavirus Disease 2019 | Biological: Tetravalent influenza virus lysis vaccine Biological: Recombinant new coronavirus vaccine (CHO cell) group |
Phase 3 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | INDUSTRY | 300 | All | 18 Years | Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, China |
2017 | Recruiting | Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19) | COVID-19 | Biological: Low dose BCD-250 injection Biological: High dose BCD-250 injection Biological: Low dose or high dose BCD-250 injection Other: Placebo injection |
Phase 2 | Biocad | INDUSTRY | 160 | All | 18 Years ~ 60 Years | UNINOVA clinic, Saint Petersburg, Russian Federation X7 Clinical Research, Saint Petersburg, Russian Federation |
2016 | Not yet recruiting | Clinical Study to Assess the Antiviral Properties of Echinaforce Reducing Oropharyngeal Concentration and Infectivity of SARS-CoV2 | SARS-CoV2 Infection | Drug: Echinaforce Forte tablets Drug: Echinaforce Chewable tablets Drug: Echinaforce tincture |
Phase 4 | A. Vogel AG, Clinical Research Centre CONVEX, Biodome Clinical, MediStat Ltd., Medical University of Graz | INDUSTRY | 75 | All | 12 Years ~ 75 Years | Diagnostics and Consultation Center Convex EOOD, Sofia, Bulgaria |
2015 | Completed | Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19 | Covid19 | Drug: Disulfiram Drug: Placebo |
Phase 2 | ETICA, Spring Research Foundation | OTHER | 140 | All | 35 Years | ETICA, Salvador, Bahia, Brazil |
2014 | Active, not recruiting | Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19 | COVID-19 | Drug: Favipiravir Other: Placebo |
Phase 3 | Giuliano Rizzardini | OTHER | 100 | All | 18 Years ~ 75 Years | Asst Fatebenefratelli Sacco, Milano, Italy |
2013 | Completed | Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ZYIL1 Following Oral Administration in Healthy Volunteers | Healthy | Drug: ZYIL1 capsule | Phase 1 | Cadila Healthcare Limited | INDUSTRY | 30 | All | 18 Years ~ 55 Years | Zydus Research Centre, Ahmedabad, Gujarat, India |
2012 | Recruiting | Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland | SARS-CoV Infection | Drug: BCG-10 vaccine Drug: 0.9% saline |
Phase 3 | Hanna Czajka, Medical Research Agency - Agencja Bada? Medycznych | OTHER | 1000 | All | 25 Years | Department of Anesthesiology and Intensive Care, University Clinical Center, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland Stefan ?eromski Specialist Hospital, Krakow, Poland Voivodeship Hospital nr 2 in the Name of The Saint Queen Jadwiga, University of Rzeszow, Poland, Rzeszow, Poland Saint Jadwiga ?l?ska Hospital, Trzebnica, Poland Department of Pediatrics, Bielanski Hospital,, Warsaw, Poland Praski Hospital, Warsaw, Poland |